BioMedNewsBreaks

ThursdayAug 19, 2021 12:53 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM), BayMedica Collaborate to Build Leading Rare Cannabinoid Company

InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids. The company is creating a pipeline of drug candidates to treat various diseases with high unmet medical needs. “In a move to grow its market presence and strengthen its operations, the company announced that it had entered into a non-binding letter of intent (“LOI”) to acquire BayMedica Inc.,” reads a recent article. “This announcement followed the two parties’ reciprocal research collaboration agreement back in November 2020, which saw them collaborate on several projects since. The agreement allowed BayMedica to assess…

Continue Reading

WednesdayAug 18, 2021 3:23 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Approval of Charter Amendment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that on Aug. 17, 2021, the stockholders approved an amendment to the company’s certificate of incorporation. The amendment, effective Aug. 17, 2021, increased the number of authorized shares of company common stock from 100,000,000 to 200,000,000. According to the update, the approval was granted at the special meeting of stockholders convened on Aug. 10, 2021, and adjourned to Aug. 17, 2021. To view the full press release, visit https://ibn.fm/8ofWr About Predictive Oncology Inc. Predictive Oncology operates through three segments…

Continue Reading

WednesdayAug 18, 2021 9:47 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Detailed Summary of National Study

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has released a detailed summary of the results from its most recent national study. Those results include the fact that one in four patients in the study who used Vivos’ FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms; that is officially defined as patients in post treatment having an Apnea Hypopnea Index (“AHI”) score of less than 5. According to the announcement, before the…

Continue Reading

TuesdayAug 17, 2021 2:51 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is focused on driving significant innovation with its drug development pipeline. Tryp is leveraging its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program in the development of treatments for chronic pain indications including fibromyalgia, phantom limb pain and complex regional pain syndrome. In addition, the company is preparing to initiate a phase 2a clinical trial for eating disorders including binge eating and hypothalamic obesity. “With the growing popularity and proliferation of psychedelics, many companies are pursuing therapeutic indications with the compounds,” reads a recent article discussing Tryp’s positioning. “However, very few have initiated phase 2a studies. Tryp Therapeutics…

Continue Reading

TuesdayAug 17, 2021 12:21 pm

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) to Demonstrate Advanced Capabilities of i/Blue Imaging System(TM) at AUA Annual Meeting

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced that the final design of its i/Blue Imaging System(TM) is on target to be demonstrated at the American Urology Association (“AUA”) Annual Meeting in September. In its 116th year, the AUA Annual Meeting is the largest gathering of urologists in the world, providing education and access to groundbreaking research, new guidelines and the latest advances in medicine for urologists and urologic health care professionals worldwide. Anticipating the ideal opportunity to address its target…

Continue Reading

TuesdayAug 17, 2021 12:03 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Seasoned Professional as US CEO

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has appointed life-sciences veteran and biomedical scientist Dr. Sunil Pandit as its new U.S. CEO; the appointment is effective as of Aug. 16, 2021. The company noted that Pandit will lead AnPac Bio’s U.S. research and development efforts, as well as ANPC’s commercialization efforts to drive adoption and growth of its Cancer Differentiation Analysis (“CDA”) technology. CDA is ANPC’s flagship product for cancer screening and early detection. Pandit has more than two decades of experience with leading precision medicine strategies, molecular and companion diagnostic…

Continue Reading

FridayAug 13, 2021 2:30 pm

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) State-of-the-Art IoT Products Provide Holistic View for Optimal Research

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is standing by to provide a wealth of smart devices, artificial intelligence and an integrated platform that will fully support the U.S. as it explores the benefits, risks and effects of cannabis. “U.S. researchers can benefit from RYAH Group’s state-of-the-art IoT suite of products. The technology collects, analyzes and leverages objective data throughout the research process. As a result, the company boasts one of the largest plant-based medicine databases globally with 200,000 plus registered users. The company’s ecosystem of products allows data to be collected from seed…

Continue Reading

FridayAug 13, 2021 10:13 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2021 Financial Results, Provides Business Outlook

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the quarter ended June 30, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. “Over the course of the second quarter, our team continued to execute on corporate, clinical and regulatory strategies to drive our Berubicin program toward regulatory approval as fast as possible. We are guided by our…

Continue Reading

FridayAug 13, 2021 9:39 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2 2021 Financial, Operational Report

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced its most recent financial report, along with operational highlights for the second quarter, the period ended June 20, 2021. In part, the report noted that second-quarter revenue totaled $4.5 million, an increase of more than 37% year over year, and 30% over the first quarter 2021; revenue for the first half of 2021 totaled $7.9 million. Gross profit for second quarter was $3.6 million with gross margin 81%…

Continue Reading

ThursdayAug 12, 2021 12:51 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Bringing Groundbreaking Tech to Push Boundaries in Neurology Space

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears poised for rapid growth as the application space for EEG-based solutions expands. “With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the company appears well-placed within the growing brain monitoring space,” reads a recent article. This comes as the brain-computer interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. It is a promising approach to overcoming paralysis by decoding brain signals…

Continue Reading